''Take solace that the only all-metastatic-cancers trial that is open (? & recruiting?) at the NCI is also using Sleeping Beauty in TCR-T.''
''(Don't be fooled by blogs that say other firms are engaged with the NCI in viral cancers or germline cancers are also metastatic cancers --- those are not metastatic and are rare in incidence).''
Wrong again. GILD had a number of CRADAs with the NCI, two of which were for TCR-T cell therapies targeting HPV16*. Data from both were published and patients had metastatic disease [1,2].
1 (see Fig. 1c, d and e) https://www.nature.com/articles/s41591-020-01225-1
2 (see Fig. 1c and d) https://ascopubs.org/doi/10.1200/JCO.18.02424
* This is the strain most likely to cause cancer and is present in close to half of all cervical, in many vaginal and vulvar, penile, anal, those of head and neck, and some other types.